---
source_pdf: "https://drive.google.com/file/d/1Z6_DpTqpyPGK2JKzO-kq46N3VwNZc-tq/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "Series B slides _ anonymized (2).pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1Z6_DpTqpyPGK2JKzO-kq46N3VwNZc-tq/view)

# SmarterDx
## Slide 1: SmarterDx - March 2024 update
SmarterDx
March 2024 update

## Slide 2: Summary
Summary
* Since May 2023 (Series A), we have increased CARR from $1.6M to $10.4M with a 90-day lag between contracted and deployed and 40% win rate.
* Our current pipeline is $70M.
* Significant investments have been made to GTM and data science teams to grow velocity by an OOM (2 new clients / year to 2 new clients / month).
* We are poised to reach $35M in CARR by EOY 2024, with a path to $65M and EBITDA profitability by EOY 2025.

Confidential. Do not distribute. SmarterDx 2024.

## Slide 3: Deep talent at the intersection of medicine, healthcare GTM, and data science
Deep talent at the intersection of medicine, healthcare GTM, and data science

**Founding team**
Mike Gao | CEO
Physician, AI at NYP

Josh Geleris | Head of Product
Physician, DS for DoD, EHR impl. at NYP

Nathan Perilo | Head of Eng
Dir., Quant Eng at Citi

**GTM**
Wayne Grodsky | CCO
CCO for EHR, ZirMed, Collective Med.

Jonathan Crawley | CFO
CFO, Collective Med., VP M&A, PointClickCare, McKinsey

Marisa Johnson | Head of Marketing
Senior Dir. Marketing at United Healthcare

**Data Science**
Scott Fleming | ML Researcher
Conor Corbin | Senior DS
Stanford ML PhDs (Nigam Shah lab), Verily

Ning Liang | Principal Eng
Founder and CTO for HealthSherpa ($140M ARR), Twitter quant

Sean Gallagher | Principal ML Eng
Created and launched Lowe's NLP team as their Principal DS

Marie Klosterman | Lead DS
Director, DS at Olive; Senior DS at Optum

Confidential. Do not distribute. SmarterDx 2024.

## Slide 4: Hospitals are eager to fix a leaky and expensive revenue cycle
Hospitals are eager to fix a leaky and expensive revenue cycle

**Intake**
Prior auth
Validate what's covered
and who pays

**Documentation**
Narrate the care provided

**CDI & Coding**
Fix documentation and
convert to structured data

**Payor validation**
Defend and receive payment

**Hard to hire**
Requires clinical expertise (e.g. nurse), which is particularly challenging today given scarcity.

**Losing money**
The average 350-bed hospital misses $22M in potential annual revenue due to RCM (Advisory Board, 2017)

**Low margins**
Median US hospital margin was 1.6% in October 2023. 2% is the 'new normal' (Health Management Academy, 2024)

**High urgency**
RCM is the top priority category for software investment (Bain, 2022)

Confidential. Do not distribute. SmarterDx 2024.

## Slide 5: Clinical documentation improvement (CDI) nurses: a hard job that's getting harder
Clinical documentation improvement (CDI) nurses: a hard job that's getting harder

Today's process
* Pick a chart
  * Prioritization
* Search data
  * NER
* ID missing Dx
* Write 'Query'
  * Templates

Confidential. Do not distribute. SmarterDx 2024.

## Slide 6: Clinical documentation improvement (CDI) nurses: a hard job that's getting harder
Clinical documentation improvement (CDI) nurses: a hard job that's getting harder

Today's process
* Pick a chart
  * Prioritization
* Search data
  * NER + rules
* ID missing Dx
* Write 'Query'
  * Templates

**Increasing complexity**
* ICD-9
* ICD-10
* MS-DRG
* APR-DRG
* Elixhauser
* HCC
* SDOH
* O/E
60,000+ diagnosis codes

**Sicker patients**
x 20 per patient

| Year | Hypertension | Hyperlipidemia | Arthritis | Diabetes | Ischemic Heart Disease | Kidney Disease | Depression |
|---|---|---|---|---|---|---|---|
| 2008 | ~18% | ~12% | ~10% | ~8% | ~5% | ~2% | ~1% |
| 2010 | ~20% | ~15% | ~12% | ~10% | ~6% | ~3% | ~2% |
| 2012 | ~25% | ~18% | ~14% | ~12% | ~7% | ~4% | ~3% |
| 2014 | ~30% | ~20% | ~16% | ~15% | ~8% | ~5% | ~4% |
| 2016 | ~35% | ~22% | ~18% | ~17% | ~9% | ~6% | ~5% |

(Note: Values are approximate estimations from the graph)

**Increased payor pushback**
* ClarisHealth
* MedReview
* OPTUM IQ
* gainwell
* COTIVITI
* Zelis.
* EQUIAN Part of OptumÂ®
* CERIS

Confidential. Do not distribute. SmarterDx 2024.

## Slide 7: This forces CDI nurses to choose between going wide or going deep.
This forces CDI nurses to choose between going wide or going deep.

**Chart: Depth of review vs. Percent of charts covered**

*   **Prioritization: Deeper but narrower**
    *   This region is in the upper-left, representing high depth of review but low percentage of charts covered.
*   **Missed opportunities:**
    *   Lost revenue (CC/MCC, SOI)
    *   Lower quality (ROM, HCC, Elix)
    *   This region is in the upper-right, representing high depth of review and high percentage of charts covered (ideal but currently missed).
*   **Rules-based: Wide but shallow**
    *   This region is in the lower-right, representing low depth of review but high percentage of charts covered.

Confidential. Do not distribute. SmarterDx 2024.

## Slide 8: We allow them to cover 100% of charts by directly inferring missing diagnoses
We allow them to cover 100% of charts by directly inferring missing diagnoses

**Today's process (crossed out)**
* Pick chart (Prioritization)
* Search data (NER + rules)
* ID missing Dx
* Write 'Query' (Templates)

**Process with SmarterDx**
*   **Ingest data**
    *   Epic, Cerner, Meditech
    *   Data transformation and normalization
*   **Infer diagnoses**
    *   Proprietary labels
    *   AutoML
    *   LLM feature extraction
    *   Mistral + Seq2Seq
    *   Counterfactual modeling
*   **Validate Dx**
    *   (Arrow from "ID missing Dx" to "Validate Dx")
*   **Copy query**
    *   Data selection
    *   LLM-generated query (BAA with OpenAI)
    *   (Arrow from "Write 'Query'" to "Copy query")

Confidential. Do not distribute. SmarterDx 2024.

## Slide 9: Higher CDI accuracy creates revenue lift worth 0.3% - 0.5% inpatient NPSR
Higher CDI accuracy creates revenue lift worth 0.3% - 0.5% inpatient NPSR

**Chart: Found revenue by customer (per month)**
**Y-axis:** Revenue ($)
**X-axis:** Date (7/1/2022, 1/1/2023, 7/1/2023, 1/1/2024)

**Data Points (Approximate values from the chart):**

| Date | Houston Methodist | Montefiore Medical Center | Beebe Healthcare | Universal Health Services | University of Arkansas | McLaren Health | White Plains Hospital | Total (Stacked) |
|---|---|---|---|---|---|---|---|---|
| 7/1/2022 | $50,000 | $20,000 | $10,000 | $0 | $0 | $0 | $0 | ~$80,000 |
| 1/1/2023 | $200,000 | $150,000 | $100,000 | $50,000 | $0 | $0 | $0 | ~$500,000 |
| 7/1/2023 | $300,000 | $200,000 | $150,000 | $100,000 | $50,000 | $0 | $0 | ~$800,000 |
| 1/1/2024 | $500,000 | $400,000 | $300,000 | $200,000 | $100,000 | $50,000 | $20,000 | ~$1,570,000 |

(Note: Values are approximate estimations from the stacked area chart)

**Legend:**
*   Houston Methodist *
*   Montefiore Medical Center *
*   Beebe Healthcare
*   Universal Health Services *
*   University of Arkansas
*   McLaren Health
*   White Plains Hospital

**Notes:**
*   ACV for these were 41% higher than predicted at time of Series A. The remainder were not in pipeline or previously deployed. This should not be extrapolated forward (as we have updated our ACV prediction).
**   Reflects a take rate of 11.6%.

**Found revenue by customer (per month)**
SmarterDx ACV: $822,000 **

Confidential. Do not distribute. SmarterDx 2024.

## Slide 10: 10 months ago, we had $18.1M in pipeline.
10 months ago, we had $18.1M in pipeline.

| Hospital |
|---|
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |
| redacted |

Confidential. Do not distribute. SmarterDx 2024.

## Slide 11: 10 months ago, we had $18.1M in pipeline. We've won $9.0M.
10 months ago, we had $18.1M in pipeline. We've won $9.0M.

| Hospital | What happened |
|---|---|
| redacted | Won [Streamline] |
| redacted | Won (vs. Iodine) [Accuity, Cloudmed] |
| redacted | Won [replaced Accuity] |
| redacted | Won |
| redacted | Won [Faircode, Cloudmed] |
| redacted | Retro / Pilot [Cloudmed] |
| redacted | Lost (Ensemble) |
| redacted | Won |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Won [Cloudmed] |
| redacted | Lost (ND) |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Lost (ND) |
| redacted | Lost (ND) |
| redacted | Won [Cloudmed] |
| redacted | Contracting (vs. Iodine) [Cloudmed] |
| redacted | Retro / Pilot |
| redacted | Won |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Mid funnel |
| redacted | Lost (R1 / Optum / Accuity) |
| redacted | Lost (Iodine) |
| redacted | Lost (ND) |
| redacted | Retro / Pilot |

Confidential. Do not distribute. SmarterDx 2024.

## Slide 12: 10 months ago, we had $18.1M in pipeline. We've won $9.0M. Customers love us.
10 months ago, we had $18.1M in pipeline. We've won $9.0M. Customers love us.

| Hospital | What happened |
|---|---|
| redacted | Won [Streamline] |
| redacted | Won (vs. Iodine) [Accuity, Cloudmed] |
| redacted | Won [replaced Accuity] |
| redacted | Won |
| redacted | Won [Faircode, Cloudmed] |
| redacted | Retro / Pilot [Cloudmed] |
| redacted | Lost (Ensemble) |
| redacted | Won |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Won [Cloudmed] |
| redacted | Lost (ND) |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Lost (ND) |
| redacted | Lost (ND) |
| redacted | Won [Cloudmed] |
| redacted | Contracting (vs. Iodine) [Cloudmed] |
| redacted | Retro / Pilot |
| redacted | Won |
| redacted | Retro / Pilot |
| redacted | Lost (ND) |
| redacted | Mid funnel |
| redacted | Lost (R1 / Optum / Accuity) |
| redacted | Lost (Iodine) |
| redacted | Lost (ND) |
| redacted | Retro / Pilot |

**SmarterDx Performance Overview**
All standard software performance indicators

**Culture**

| Metric | (n=) | Score |
|---|---|---|
| Keeps all promises (percent of respondents who answered yes) | (n=4) | 100% |
| Proactive service (1-9 scale) | (n=4) | A+ |
| Product works as promoted (1-9 scale) | (n=4) | A+ |

**Loyalty**

| Metric | (n=) | Score |
|---|---|---|
| Forecasted satisfaction (1-9 scale) | (n=4) | A+ |
| Likely to recommend (1-9 scale) | (n=4) | A+ |
| Overall satisfaction (1-9 scale) | (n=4) | A+ |
| Part of long-term plans (percent of respondents who answered yes) | (n=4) | 100% |
| Would you buy again (percent of respondents who answered yes) | (n=4) | 100% |

**Operations**

| Metric | (n=) | Score |
|---|---|---|
| Ease of use (1-9 scale) | (n=4) | A+ |
| Quality of implementation (1-9 scale) | (n=4) | A+ |
| Quality of training (1-9 scale) | (n=4) | A+ |

**Product**

| Metric | (n=) | Score |
|---|---|---|
| Delivery of new technology (1-9 scale) | (n=4) | A+ |
| Overall product quality (1-9 scale) | (n=4) | A+ |
| Product has needed functionality (1-9 scale) | (n=4) | A |
| Supports integration goals (1-9 scale) | (n=4) | B+ |

**Relationship**

| Metric | (n=) | Score |
|---|---|---|
| Executive involvement (1-9 scale) | (n=4) | A+ |
| Quality of phone/web support (1-9 scale) | (n=4) | A+ |

**Value**

| Metric | (n=) | Score |
|---|---|---|
| Avoids charging for every little thing (percent of respondents who answered yes) | (n=4) | 100% |
| Drives tangible outcomes (1-9 scale) | (n=4) | A+ |
| Money's worth (1-9 scale) | (n=4) | A+ |

Confidential. Do not distribute. SmarterDx 2024.

## Slide 13: 10 months ago, we had $18.1M in pipeline. We've won $9.0M. Customers love us. This has translated to a $69.5M pipeline across four RVPs, Wayne, and Mike.
10 months ago, we had $18.1M in pipeline. We've won $9.0M. Customers love us.
This has translated to a $69.5M pipeline across four RVPs, Wayne, and Mike.

**Q1**
*   redacted
    *   ACV $1.1M
    *   Won vs. Iodine
*   redacted
    *   ACV $1.7M
    *   Closed
    *   First contact in November

**Q2**
*   redacted
    *   ACV $2.9M
    *   In contracting
    *   Won vs. Iodine
    *   First contact in November
*   redacted
*   redacted
    *   ACVs $1.3M and $3.1M
    *   CFO-driven
    *   In assessment
    *   First contact in November

**Q3**
*   redacted
    *   ACV $3.6M
    *   Late-stages
    *   System-wide
*   redacted
*   redacted
    *   ACVs $2.6M and $1.0M
    *   In assessment
*   redacted
    *   ACV $4.5M
    *   Early stages

Confidential. Do not distribute. SmarterDx 2024.

## Slide 14: Prebill alone can reach significant ARR in 2025
Prebill alone can reach significant ARR in 2025

**Chart: Prebill projected CARR and gross profit (annualized)**
**Y-axis:** Dollars ($)
**X-axis:** Date (7/1/2023, 1/1/2024, 7/1/2024, 1/1/2025, 7/1/2025)

**Data Points (Approximate values from the chart):**

| Date | CARR ($M) | Gross profit ($M) |
|---|---|---|
| 7/1/2023 | ~$1M | ~$0.5M |
| 1/1/2024 | ~$7M | ~$2M |
| 7/1/2024 | ~$30M | ~$10M |
| 1/1/2025 | ~$45M | ~$25M |
| 7/1/2025 | ~$65M | ~$40M |

(Note: Values are approximate estimations from the line chart)

**Legend:**
*   CARR (blue shaded area)
*   Gross profit (green shaded area)

Confidential. Do not distribute. SmarterDx 2024.

## Slide 15: Prebill R&D positions us for upstream and downstream adjacencies
Prebill R&D positions us for upstream and downstream adjacencies

| | Historic R&D | Current R&D | Unlocks |
|---|---|---|---|
| **Data and Integration** | Clinical data (Epic, Meditech, Cerner), Billing data | HL7v2, FHIR, Charges, Payments | Utilization management |
| **Algorithms** | Diagnosis predictions | (Further improvements) | Clinical variability |
| **Visualization & Query writer** | Relationships between diagnoses and explanatory data | Improved summarization | Denials / appeals writer |

Confidential. Do not distribute. SmarterDx 2024.

## Slide 16: (Financial Table)
| | 2022 | 2023 | 2024 (Budget) | 2024 (Re-Forecast) | 2025 Forecast | 2026 Forecast | 2027 Forecast |
|---|---|---|---|---|---|---|---|
| Contracted Sites | 4 | 13 | 24 | 29 | 55 | 95 | 138 |
| FTE | 13 | 38 | 105 | 154 | 246 | 403 | 566 |
| CARR ($M) | 1.6 | 7.4 | 25.9 | 35.3 | 72.8 | 139.0 | 210.8 |
| YoY Growth % | - | 365% | 250% | 377% | 106% | 91% | 52% |
| Deployed ARR ($M) | 1.4 | 3.9 | 21.5 | 26.9 | 60.6 | 117.8 | 189.6 |
| Revenue ($M) | 0.4 | 1.8 | 11.7 | 11.2 | 45.0 | 88.8 | 155.3 |
| YoY Growth % | - | 299% | 555% | 528% | 301% | 98% | 75% |
| COGS ($M) | 0.1 | 1.0 | 4.5 | 4.7 | 11.1 | 20.8 | 33.7 |
| GM % | 71% | 46% | 62% | 58% | 75% | 77% | 78% |
| OpEx ($M) | 1.9 | 6.3 | 16.0 | 21.5 | 40.6 | 62.0 | 90.5 |
| Cash Burn (excl. Financing) ($M) | (1.7) | (5.7) | (11.9) | (18.7) | (14.9) | (10.1) | 0.6 |

Confidential. Do not distribute. SmarterDx 2024.